Rare yeasts (non-Candida, non-Cryptococcus) are increasingly recognized as the cause of invasive fungal infections (IFI) [1,2]. The genus Blastobotrys is an industrially important yeast that is used to synthesize various biotechnological products [3]. Although the genus Blastobotrys has not been well recognized as a human pathogen, several cases of human infections have recently been reported [[4], [5], [6], [7], [8], [9], [10]]. Blastobotrys mokoenaii was initially described as Candida mokoenaii in 2000 [11]. It was reassigned to the genus Blastobotrys by Kurtzman and Robnett in 2007 [12]. To the best of our knowledge, there have been no reported cases of human B. mokoenaii infection.

Here, we report a case of IFI caused by B. mokoenaii with reduced susceptibility to multiple antifungal agents. The patient was immunocompromised with chemotherapy followed by allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT) for acute myeloid leukemia (AML).